Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ruby Birk"'
Autor:
Peter R. Bremner, Ruby Birk, Noushin Brealey, Afisi S. Ismaila, Chang-Qing Zhu, David A. Lipson
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obs
Externí odkaz:
https://doaj.org/article/ccd29838d82b4091a09d185b46fc79d5
Autor:
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner
Publikováno v:
ERJ Open Research, Vol 4, Iss 4 (2018)
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD). We prospectively analysed CID in the
Externí odkaz:
https://doaj.org/article/1c24a94a5bb24daeb8ac4f1810b76339
Autor:
David M.G. Halpin, Ruby Birk, Noushin Brealey, Gerard J. Criner, Mark T. Dransfield, Emma Hilton, David A. Lomas, Chang-Qing Zhu, David A. Lipson
Publikováno v:
ERJ Open Research, Vol 4, Iss 2 (2018)
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the b
Externí odkaz:
https://doaj.org/article/1dc7064705e44d09904b25cafb551f4a
Publikováno v:
Advances in Therapy
Introduction Few studies have utilized 24-h serial spirometry to compare the effects of inhaled chronic obstructive pulmonary disease (COPD) therapies on lung function. The FULFIL study previously reported significant lung function improvements with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::988b40c1577d5911e21431132dd47cea
https://pubmed.ncbi.nlm.nih.gov/33011864
https://pubmed.ncbi.nlm.nih.gov/33011864
Autor:
Noushin Brealey, Steve Pascoe, Chang-Qing Zhu, Ruby Birk, Nicholas Locantore, David A. Lomas, David A. Lipson, Maggie Tabberer
Publikováno v:
Advances in Therapy
Introduction Directly recorded patient experience of symptoms and health-related quality of life (HRQoL) can complement lung function and exacerbation rate data in chronic obstructive pulmonary disease (COPD) clinical studies. The FULFIL study record
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3f7d8d8a018b416a2f74226493a3c0f
http://europepmc.org/articles/PMC5778187
http://europepmc.org/articles/PMC5778187
Autor:
David A. Lomas, Nicholas Locantore, Steven Pascoe, Andrea Ludwig-Sengpiel, Noushin Brealey, David A. Lipson, Ruby Birk, Chang-Qing Zhu, Helen Barnacle, Maggie Tabberer, Rajat Mohindra
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 196:438-446
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.Objectives: We compared the effects of once-da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d5adf5cd9b77e7dc2ab9eea9589dbc5
https://doi.org/10.1164/rccm.201703-0449oc
https://doi.org/10.1164/rccm.201703-0449oc
Publikováno v:
Clinical Pharmacokinetics
Background Population pharmacokinetic methods were used to characterize the pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb0cf762036b9ebb883f0b7b9d0870e
https://pubmed.ncbi.nlm.nih.gov/31321713
https://pubmed.ncbi.nlm.nih.gov/31321713
Autor:
Chris Compton, Afisi S. Ismaila, Chang-Qing Zhu, Ruby Birk, David A. Lipson, Noushin Brealey, Maggie Tabberer, Gerard J. Criner, Ian Naya
Publikováno v:
ERJ Open Research
ERJ Open Research, Vol 4, Iss 4 (2018)
ERJ Open Research, Vol 4, Iss 4 (2018)
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD). We prospectively analysed CID in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::415948ee7fa09d08d47091d88944f435
http://europepmc.org/articles/PMC6168763
http://europepmc.org/articles/PMC6168763
Autor:
Misba Beerahee, Chang-Qing Zhu, David A. Lipson, Noushin Brealey, Ruby Birk, Eleni Pefani, Rashmi Mehta, Helen Barnacle
Publikováno v:
Journal of Clinical Pharmacology
A population pharmacokinetic analysis was conducted from a subset of samples obtained from the Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy trial to characterize the pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3c47c0bb6d7a5b0a91ac15f82dc0c55
https://pubmed.ncbi.nlm.nih.gov/29762864
https://pubmed.ncbi.nlm.nih.gov/29762864
Autor:
C-Q Zhu, G.J. Criner, Ruby Birk, David A. Lipson, Emma Hilton, Dmg Halpin, Noushin Brealey, David A. Lomas, Mark T. Dransfield
Publikováno v:
Pharmacotherapies for COPD.
Results from FULFIL have shown statistically significant improvements in lung function and health-related quality of life, and a reduction in exacerbation rates with once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100 µg/62.5 µg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45479da9d02e8094bde3bcd01e1db01a
https://doi.org/10.1136/thoraxjnl-2017-210983.414
https://doi.org/10.1136/thoraxjnl-2017-210983.414